| Literature DB >> 22927892 |
D Esmaeili1, A Mohabati Mobarez, A Tohidpour.
Abstract
BACKGROUND: Helicobacter pylori, an infective agent of more than 50% of the world population is prominent to be the main causative factor in the etiologies of chronic, active or type B gastritis, peptic and duodenal ulcer, gastric carcinoma, and mucosa-associated lymphoid tumors. A high prevalence of this bacterium in dental plaque is always reported. Pharmacological treatment of H. pylori infections includes administration of 3-fold therapeutic regimens which are typically used to suppress H. pylori activity. However, antibiotic resistance frequently develops as a consequence of such treatment. Thus, searching for alternative therapies for H. pylori infections is of special interest.Entities:
Keywords: Eucalyptus globulus.; Helicobacter pylori; Shoya; Thymus vulgaris
Year: 2012 PMID: 22927892 PMCID: PMC3426772 DOI: 10.2174/1874285801206010065
Source DB: PubMed Journal: Open Microbiol J ISSN: 1874-2858
Antimicrobial Activity of Thymus Vulgaris and Eucalyptus Globulus Essential Oils Serial Dilutions Against H. Pylori ATCC 700392
| H. Pylori Growth | Eucalyptus Globules (µg/ml) | H. pylori Growth | Thymus Vulgaris (µg/ml) |
|---|---|---|---|
| + | 5.8 | + | 5.4 |
| + | 11.6 | – | 10.8 |
| + | 23.2 | – | 21.2 |
| – | 46.4 | – | 42.4 |
| – | 92.8 | – | 84.8 |
Antimicrobial Activity of Shoya Powder Suspensions Against H. Pylori ATCC 700392
| Inhibition Zone (mm) | Visible Growth | Suspension Dilutions (mg/ml) |
|---|---|---|
| 16 | – | 1/10(10-1) |
| 16 | – | 1/100(10-2) |
| 15.5 | – | 1/1000(10-3) |
| 15 | – | 1/10000(10-4) |
| 14 | – | 1/100000(10-5) |
| 12 | + | 1/1000000(10-6) |
Serological Analysis of Variable Titers of IgA and IgG in Mice Challenged with H. Pylori and Treated with Shoya During 4 Months
| T3 | T2 | T1 | Tested Mice | |||
|---|---|---|---|---|---|---|
| T3 | T2 | T1 | ||||
| IgG | IgA | IgG | IgA | IgG | IgA | |
| 4±0.23 | 5±0.27 | 21±0.88 | 30±0.12 | 3±1.23 | 6 ±1.34 | 1 |
| 2±1.21 | 3±1.61 | 18±0.97 | 27±0.39 | 2±1.11 | 5 ± 1.29 | 2 |
| 2±2.13 | 8±1.81 | 7±2.11 | 35±0.99 | 3±0.78 | 7.5 ±1.2 | 3 |
| 2±1.33 | 4±2.20 | 7±1.21 | 15±1.11 | 4±0.93 | 8 ± 1.02 | 4 |
| 2±0.87 | 3±1.23 | 8±1.29 | 12±1.21 | 2±1.24 | 3.5 ±1.48 | 5 |
| 2±1.12 | 3±2.48 | 7±2.11 | 13±1.43 | 2.5±1.78 | 4 ± 1.11 | 6 |
| 2±0.89 | 3.5±1.11 | 6±0.22 | 17±1.65 | 3±2.13 | 5± 1.42 | 7 |
| 3±0.79 | 9±7.40 | 15±1.15 | 45±0.34 | 4±2.53 | 9 ± 1.63 | 8 |
| 3±1.26 | 4±2.01 | 15±1.10 | 19±0.84 | 5±2.36 | 6.5 ±.12 | 9 |
| 2.5±2.01 | 3.5±1.22 | 16±1.17 | 23.5±0.38 | 6±0.79 | 7 ± 1.43 | 10 |
| 3±0.96 | 4±2.43 | 16±2.11 | 28.5±1.41 | 5±0.63 | 9 ± 2.18 | 11 |
| 3±1.24 | 3±0.75 | 17±1.19 | 29±1.32 | 3±2.16 | 4 ± 1.21 | 12 |
| 3.5± 1.09 | 4±1.88 | 11±1.32 | 12±1.65 | 2.5±2.32 | ± 2.423 | 13 |
| 2.5±2.11 | 4±1.37 | 12±0.86 | 14±1.67 | 2±.94 | 3.5 ±0.89 | 14 |
| 2.5±1.31 | 3±2.17 | 12±1.53 | 17±2.22 | 2±1.37 | 3 ±0.96 | 15 |
Titers of specific anti-H. pylori IgA and IgG in tested mice sera before challenging with H. pylori
Titers of specific anti-H. pylori IgA and IgG in mice sera two weeks after challenging with H. pylori.
final titers of IgA and IgG in mice infected with H. pylori and treated two weeks with Shoya suspension. Antibody levels are shown as Mean ± SD of ODR per microgram of protein units for anti H.pylori IgG and IgA.